Skip to main content

Testing T2D2 in a mouse model of Idiopathic Pulmonary Fibrosis (IPF)

Project Member(s): Hansbro, P.

Funding or Partner Organisation: Next Science IP Holdings Pty Limited
Next Science IP Holdings Pty Limited

Start year: 2021

Summary: We have previously completed a proof-of-principle experiment where we tested the compounds in mice infected with influenza. While treatment did increase BAL inflammation, it reduced lung inflammation as well as collagen deposition suggesting it might be a potential treatment for IPF. We will now test their compound T2D2 in our mouse model of IPF.

FOR Codes: Cardiovascular medicine and haematology, Respiratory System and Diseases (incl. Asthma), Clinical health